Evidence map›Paper›PMID 35855055›Full record

SynthesisInternational journal of clinical practice2022

Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis.

Lei Zhang, Hong Wang, Jizheng Tian, Lili Sui, Xiaoyan Chen

Abstract readMeta-AnalysisReview
In one paragraph

Synthesis in International journal of clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lei ZhangDepartment of Oncology, The Hospital of Shunyi District of Beijing, Beijing 101300, China.
Hong WangDepartment of Oncology, The Hospital of Shunyi District of Beijing, Beijing 101300, China.
Jizheng TianDepartment of Oncology, The Hospital of Shunyi District of Beijing, Beijing 101300, China.
Lili SuiDepartment of Oncology, The Hospital of Shunyi District of Beijing, Beijing 101300, China.
Xiaoyan ChenDepartment of Oncology, The Hospital of Shunyi District of Beijing, Beijing 101300, China.ORCID https://orcid.org/0000-0001-6438-7927

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins are suggested to improve cancer survival by possible anti-inflammatory effect. However, it remains unclear if concomitant use of statins could improve the efficacy of immune checkpoint inhibitors (ICIs) in patients with non-small-cell lung cancer (NSCLC). Accordingly, a meta-analysis was performed to systematically evaluate the effect of concomitant statins in NSCLC patients receiving ICIs. Relevant studies were obtained by literature search in PubMed, Embase, and Web of Science databases. A conservative random-effect model was used to combine the results. Eight cohorts including 2382 patients were included. The programmed death-1/ligand-1 inhibitors were used in seven studies; while the cytotoxic T-lymphocyte-associated protein 4 inhibitors were used in the other study. It was shown that concomitant use of statin did not significantly affect the progression-free survival (PFS, hazard ratio (HR): 0.86, 95% confidence interval (CI): 0.70 to 1.07,

Indexed as

Carcinoma, Non-Small-Cell LungHydroxymethylglutaryl-CoA Reductase InhibitorsImmune Checkpoint InhibitorsLung NeoplasmsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsImmune Checkpoint Inhibitors

Identifiers

PMID35855055
PMCPMC9276478

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.